Skip to main content

SOLENO THERAPEUTICS INC

corporate_fare Company Profile

SOLENO THERAPEUTICS INC

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SLNO - Latest Insights

SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
SLNO
Apr 20, 2026, 8:53 AM EDT
Filing Type: SC 14D9
Importance Score:
10
SLNO
Apr 20, 2026, 7:36 AM EDT
Filing Type: SC TO-T
Importance Score:
10
SLNO
Apr 07, 2026, 1:15 PM EDT
Source: Reuters
Importance Score:
7
SLNO
Apr 06, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
SLNO
Apr 06, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
10
SLNO
Apr 06, 2026, 7:39 AM EDT
Filing Type: SC TO-C
Importance Score:
10
SLNO
Apr 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
SLNO
Mar 16, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
7
SLNO
Feb 26, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
7
SLNO
Feb 25, 2026, 4:34 PM EST
Filing Type: 10-K
Importance Score:
9
SLNO
Feb 25, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
SLNO
Jan 23, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
SLNO
Jan 12, 2026, 8:51 AM EST
Filing Type: 8-K
Importance Score:
8